搜索

quanfu quanfu

Product Center

Homepage
/
News
/
Company news
/
Ab&B Bio-Tech CO.,LTD.JS Tetravalent Influenza Virus Subunit Vaccine Approved for Launch

Ab&B Bio-Tech CO.,LTD.JS Tetravalent Influenza Virus Subunit Vaccine Approved for Launch

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2023-05-18
  • Views:

(Summary description)Recently, Ab&B Bio Tech CO., LTD. JS independently developed a full dose adjuvant free tetravalent influenza virus subunit vaccine (Huier Anti New HRK-X) ®） The listing application has been approved by the National Drug Administration (NMPA), which is the first approved tetravalent influenza virus subunit vaccine in China.

Ab&B Bio-Tech CO.,LTD.JS Tetravalent Influenza Virus Subunit Vaccine Approved for Launch

(Summary description)Recently, Ab&B Bio Tech CO., LTD. JS independently developed a full dose adjuvant free tetravalent influenza virus subunit vaccine (Huier Anti New HRK-X) ®） The listing application has been approved by the National Drug Administration (NMPA), which is the first approved tetravalent influenza virus subunit vaccine in China.

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2023-05-18 11:00
  • Views:
Information
Recently, Ab&B Bio Tech CO., LTD. JS independently developed a full dose adjuvant free tetravalent influenza virus subunit vaccine (Huier Anti New HRK-X) ®） The listing application has been approved by the National Drug Administration (NMPA), which is the first approved tetravalent influenza virus subunit vaccine in China.
 
 
Source: Government Service Portal of the State Drug Administration
 
Huier Kangxin only extracts effective antigens, which have the characteristics of high purity, low vaccination side effects, good safety and comprehensive protection, and belong to the first category of preventive biological products. The clinical trial results all reached the clinical endpoints and were published in the international authoritative journal Vaccine, and were cited by the "Technical Guidelines for Influenza Vaccination in China (2021-2022)" and "Technical Guidelines for Influenza Vaccination in China (2022-2023)" respectively .
 
Clinical results show that Huier Kangxin is a safe and effective influenza vaccine, which can provide broader and sufficient protection against seasonal influenza viruses. The vaccine is expected to serve as an important member of the influenza prevention strategy and contribute to the global prevention and control of influenza virus outbreaks.
 
 
Ab&B Bio-Tech CO.,LTD.JS is committed to the research and development, registration declaration, industrial production and sales of innovative human vaccines. Aim at international standards and carry out independent innovation research and development. Up to now, quadrivalent influenza virus subunit vaccine (6-35 months old), quadrivalent influenza virus subunit vaccine (3 years old and above), 23-valent pneumococcal polysaccharide vaccine, freeze-dried human rabies vaccine (human two Ploid cells) and other new drug clinical approval documents, clinical trials and NDA declarations are being carried out in an orderly manner.
 
In recent years, the company has continued to increase investment in research and development, and the Shanghai/Taizhou R&D Center and the pilot test platform are advancing a number of viral vaccines, bacterial vaccines, conjugate vaccines, recombinant subunit vaccines and mRNA vaccine pipelines simultaneously.
 
Do not simply copy, aim at the international trend, and make innovative vaccines are the project principles of Ab&B Bio-Tech CO.,LTD.JS. Caring for life and protecting health is the mission of Ab&B Bio-Tech CO.,LTD.JS! Ab&B Bio-Tech CO.,LTD.JS will carry forward the spirit of innovation, pragmatism, self-discipline, integrity, and persistent struggle, so that China can use global innovative vaccines and the world can use Chinese high-quality vaccines!
 
Scan the QR code to read on your phone
Previous: The Mid Year Marketing Conference and Promoter Strategic Cooperation Conference have been successfully held
Next: Ab&B Bio-Tech CO.,LTD.JS has developed the world's first broad-spectrum mRNA vaccine against smallpox virus
Previous: The Mid Year Marketing Conference and Promoter Strategic Cooperation Conference have been successfully held
Next: Ab&B Bio-Tech CO.,LTD.JS has developed the world's first broad-spectrum mRNA vaccine against smallpox virus

Relevant information

Have a project？Get a touch!

Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio

Contact

E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City

Quick view

Follow us

Copyright © 2022 Ab&B Bio-Tech CO.,LTD.JS All Rights Reserved.   Powered by:www.300.cn
Verification 苏ICP备16005775号-1
Search